LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Probe Lights Up Staph Infections

By LabMedica International staff writers
Posted on 17 Feb 2014
Image: University of Iowa researchers have created a noninvasive probe that can detect a common strain of staph bacteria in the body. The staph bacteria are located via a light-emitting molecule (green), which is released when a bacterial enzyme (in orange) slices and separates the probe (shown in blue), shown in the illustration above (Photo courtesy of McNamara lab, University of Iowa).
Image: University of Iowa researchers have created a noninvasive probe that can detect a common strain of staph bacteria in the body. The staph bacteria are located via a light-emitting molecule (green), which is released when a bacterial enzyme (in orange) slices and separates the probe (shown in blue), shown in the illustration above (Photo courtesy of McNamara lab, University of Iowa).
A novel chemical probe comprising a self-quenching fluorescently labeled oligonucleotide allows for the rapid, noninvasive detection of staphylococcal (staph) infections.

To more easily identify sites of staph infection investigators at the University of Iowa (Iowa City, USA) created a novel molecular probe. The probe comprised a pair of deoxythymidines flanked by several 2′-O-methyl–modified nucleotides. Various chemical modifications rendered the molecule resistant to mammalian serum nucleases while leaving it susceptible to the action of staphylococcal micrococcal nuclease (MN). A fluorophore was attached to one end of the probe while a molecule that quenched the fluorescence was attached to the other. The presence of the quencher prevented emission of any fluorescent light.

The action of Staphylococcus aureus MN, an endo-exonuclease that digests single-stranded and double-stranded DNA and RNA, digested the probe and liberated the fluorophore from the suppressing effect of the quencher. As the probe was susceptible to digestion only by staph MN, the appearance of fluorescence pinpointed the site of bacterial infection.

The probe's fluorescence was activated in culture supernatants of S. aureus but not in culture supernatants of several other pathogenic bacteria. Systemic administration of this probe to mice bearing S. aureus muscle infections resulted in probe activation at the infection sites in an MN-dependent manner.

"We have come up with a new way to detect staph bacteria that takes less time than current diagnostic approaches," said senior author Dr. James McNamara, assistant professor of internal medicine at the University of Iowa. "It builds on technology that has been around a long time, but with an important twist that allows our probe to be more specific and to last longer. If the probe gets cleaved by serum nucleases, then our probe would be lit up all over the bloodstream. But since it is split only by staph nucleases, then we can pinpoint where the staph bacteria are active."

The investigators applied for US patent to protect use of the molecule in the fall of 2012, and plan to refine the probe so it can be detected deeper in the body and with catheter infections.

A paper describing the novel probe for staph infections was published in the February 2, 2014, online edition of the journal Nature Medicine.

Related Links:

University of Iowa


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more